DiaMedica Therapeutics Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
DiaMedica Therapeutics Inc. (DMAC) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $4.61 per share as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2026-08-10
- 2019-03-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price 5.77 CAD.
- 2018-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price 7.87 CAD.
CAD
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2019-03-31 | 5.77 CAD 10-Q · filed 2019-05-13 |
| 2018-12-31 | 7.87 CAD 10-K · filed 2019-03-19 |
USD/shares
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $4.61 10-Q · filed 2026-08-10 |
| 2026-03-31 | $4.23 10-Q · filed 2026-05-06 |
| 2025-12-31 | $4.11 10-K · filed 2026-03-30 |
| 2025-09-30 | $3.99 10-Q · filed 2025-11-12 |
| 2025-06-30 | $3.70 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.56 10-Q · filed 2025-05-13 |
| 2024-12-31 | $3.33 10-K · filed 2025-03-17 |
| 2024-09-30 | $3.31 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.31 10-Q · filed 2024-08-07 |
| 2024-03-31 | $3.52 10-Q · filed 2024-05-08 |
| 2023-12-31 | $3.61 10-K · filed 2024-03-19 |
| 2023-09-30 | $3.66 10-Q · filed 2023-11-13 |
| 2023-06-30 | $3.69 10-Q · filed 2023-08-14 |
| 2023-03-31 | $4.10 10-Q · filed 2023-05-15 |
| 2022-12-31 | $4.12 10-K · filed 2023-03-28 |
| 2022-09-30 | $4.15 10-Q · filed 2022-11-09 |
| 2022-06-30 | $4.37 10-Q · filed 2022-08-11 |
| 2022-03-31 | $4.88 10-Q · filed 2022-05-04 |
| 2021-12-31 | $5.25 10-K · filed 2022-03-14 |
| 2021-09-30 | $5.63 10-Q · filed 2021-11-10 |
| 2021-06-30 | $5.63 10-Q · filed 2021-08-11 |
| 2021-03-31 | $5.60 10-Q · filed 2021-05-05 |
| 2020-12-31 | $5.33 10-K · filed 2021-03-10 |
| 2020-09-30 | $5.24 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.19 10-Q · filed 2020-08-11 |
| 2020-03-31 | $5.21 10-Q · filed 2020-05-13 |
| 2019-12-31 | $5.33 10-K · filed 2020-03-23 |
| 2019-09-30 | $5.38 10-Q · filed 2019-11-13 |
| 2019-06-30 | $5.41 10-Q · filed 2019-08-13 |
CAD/shares
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2019-03-31 | 5.77 CAD/shares 10-Q · filed 2019-05-13 |
| 2018-12-31 | 7.87 CAD/shares 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |